Evercore ISI Group Downgrades Occidental Petroleum to Underperform, Lowers Price Target to $60

Evercore ISI Group analyst Stephen Richardson downgrades Occidental Petroleum (NYSE:OXY) from In-Line to Underperform and lowers the price target from $74 to $60.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Evercore ISI Group analyst Stephen Richardson downgrades Occidental Petroleum (NYSE:OXY) from In-Line to Underperform and lowers the price target from $74 to $60.

RCI Hospitality Holdings Q4 Adj. EPS $1.58 May Not Compare To $0.67 Estimate, Sales $54.90M Miss $55.43M Estimate

By Bill Haddad

Today, 11:41 PM

RCI Hospitality Holdings (NASDAQ:RICK) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $0.67 by 135.82 percent. This is a 953.33 percent increase over earnings of $0.15 per

RICK

Morgan Stanley Maintains Underweight on Citigroup, Lowers Price Target to $44

By Benzinga Newsdesk

Today, 11:41 PM

Morgan Stanley analyst Betsy Graseck maintains Citigroup (NYSE:C) with a Underweight and lowers the price target from $46 to $44.

Credit Suisse Maintains Outperform on Fulcrum Therapeutics, Raises Price Target to $30

By Benzinga Newsdesk

Today, 11:41 PM

Credit Suisse analyst Judah Frommer maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and raises the price target from $20 to $30.

FULC

Leonardo DRS Awarded $579M Contract For Advanced Thermal Weapon Sights Over Five Years

By Benzinga Newsdesk

Today, 11:41 PM

Leonardo DRS, Inc. ("DRS") announced today that it has received a contract to produce its next-generation thermal weapon sights for the U.S. Army. The firm-fixed-price contract from the U.S. Army Contracting Command is valued at $579 million over five years.

RADA

Evercore ISI Group Downgrades Occidental Petroleum to Underperform, Lowers Price Target to $60

Related Posts

RCI Hospitality Holdings Q4 Adj. EPS $1.58 May Not Compare To $0.67 Estimate, Sales $54.90M Miss $55.43M Estimate

Morgan Stanley Maintains Underweight on Citigroup, Lowers Price Target to $44

Credit Suisse Maintains Outperform on Fulcrum Therapeutics, Raises Price Target to $30

Leonardo DRS Awarded $579M Contract For Advanced Thermal Weapon Sights Over Five Years